Celcuity Inc. (CELC)
Largest Insider Buys in Sector
CELC Stock Price History Chart
CELC Stock Performance
About Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with …
Insider Activity of Celcuity Inc.
Over the last 12 months, insiders at Celcuity Inc. have bought $0 and sold $28,032 worth of Celcuity Inc. stock.
On average, over the past 5 years, insiders at Celcuity Inc. have bought $850,494 and sold $114,142 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $103,187 was made by Furcht Leo (director) on 2023‑05‑22.
List of Insider Buy and Sell Transactions, Celcuity Inc.
| 2024-10-23 | Sale | director | 350 0.0009% | $16.25 | $5,688 | 0.00% | ||
| 2024-08-23 | Sale | director | 350 0.0009% | $16.95 | $5,933 | -13.78% | ||
| 2024-06-21 | Sale | director | 350 0.0011% | $15.68 | $5,488 | -4.17% | ||
| 2024-04-24 | Sale | director | 350 0.0011% | $17.06 | $5,971 | -7.97% | ||
| 2024-02-21 | Sale | director | 350 0.0014% | $14.15 | $4,953 | +10.98% | ||
| 2023-12-20 | Sale | director | 350 0.0015% | $14.37 | $5,030 | +9.16% | ||
| 2023-12-15 | Sale | director | 2,940 0.0121% | $14.57 | $42,847 | +6.44% | ||
| 2023-12-14 | Sale | director | 5,000 0.0206% | $14.75 | $73,752 | +5.69% | ||
| 2023-12-13 | Sale | director | 5,000 0.0202% | $14.50 | $72,500 | +5.56% | ||
| 2023-12-12 | Sale | director | 2,060 0.0085% | $14.61 | $30,089 | +6.46% | ||
| 2023-12-08 | Sale | director | 5,000 0.0207% | $15.00 | $75,000 | +4.69% | ||
| 2023-12-07 | Sale | director | 5,000 0.0207% | $14.85 | $74,250 | +5.34% | ||
| 2023-10-25 | Sale | director | 350 0.0016% | $10.23 | $3,581 | +52.29% | ||
| 2023-08-30 | Sale | director | 350 0.0015% | $9.28 | $3,248 | +55.93% | ||
| 2023-08-23 | Sale | director | 300 0.0013% | $9.82 | $2,946 | +45.96% | ||
| 2023-06-23 | Sale | director | 300 0.0014% | $11.79 | $3,537 | +25.91% | ||
| 2023-05-23 | Sale | director | 75 0.0003% | $11.10 | $833 | +20.73% | ||
| 2023-05-22 | Sale | director | 100 0.0005% | $10.50 | $1,050 | +24.01% | ||
| 2023-05-22 | director | 10,000 0.0449% | $10.32 | $103,187 | +24.01% | |||
| 2023-05-19 | Sale | director | 250 0.0011% | $9.85 | $2,463 | +25.54% |
Insider Historical Profitability
| Sullivan Brian F. | Chief Executive Officer | 3016643 8.1246% | $12.42 | 1 | 0 | +9.38% |
| NIGON RICHARD | director | 96032 0.2586% | $12.42 | 7 | 0 | +17.9% |
| Furcht Leo | director | 10250 0.0276% | $12.42 | 1 | 0 | +24.01% |
| Murphy Polly A. | director | 5000 0.0135% | $12.42 | 1 | 0 | +10.68% |
Institutional Investor Ownership
| Perceptive Advisors | $51.03M | 6.73 | 2.36M | +59.47% | +$19.03M | 0.03 | |
| Morgan Stanley | $50.75M | 6.69 | 2.35M | +7.02% | +$3.33M | <0.01 | |
| Soleus Capital Management, L.P. | $37.4M | 4.93 | 1.73M | -20.56% | -$9.68M | 0.16 | |
| Commodore Capital, LP | $33.61M | 4.43 | 1.56M | -11.33% | -$4.29M | 0.13 | |
| Baker Bros Advisors LP | $33.53M | 4.42 | 1.55M | +189.92% | +$21.97M | 0.24 |